

Supplementary Table 2. Description of hypocalcemia after denosumab withdrawal (N=15)

Sex/ Age	Time from last denosumab (months)	Ca (8.8–10.7 mg/dL)	Albumin (3.5–5.2 g/dL)	Albumin- corrected Ca	Ionized Ca (1.13–1.32 mmol/L)	Creatinine (0.5–1.2 mg/dL)	Phosphate (2.5–4.5 mg/dL)	Mg (1.7–2.6 mg/dL)	Notes	Calcium IV treatment
M/84	4	8.3	3.8	-	-	0.83	2.3	1.7	Good clinical status	No
F/45	4	8.4	3.4	8.5	-	1.41	3.0	2.0	Hospitalization for abdominal pain (peritoneal disease)	No
F/59	2	8.7	3.8	-	-	0.67	-	-	Stable disease at CT scan performed 5 days before; evidence of progression in bone, pulmonary and liver after one month	No
M/44	6	8.0	5.0	-	-	0.89	-	-	CNS progression, poor performance status	Yes
M/59	2	8.0	4.2	-	-	0.74	2.3	2.1	Peritoneal nodule progression	No
F/64	1	8.6	4.4	-	-	0.90	4.0	2.2	Recent RT to bone metastasis (rib)	No
F/69	41	8.4	3.9	-	-	0.57	-	-	On zoledronic acid (last infusion 3 months before)	No
F/57	4	8.6	3.7	-	-	0.57	-	2.1	Recent abdominal pain and liver function abnormalities	No
F/70	31	8.8	-	-	1.07	0.66	-	1.0	During hospitalization due to osteoradionecrosis of mandible and acute respiratory insufficiency	Yes
F/65	7	8.6	4.2	-	-	1.17	-	-	Recent evidence of progression in the liver	No
F/76	14	8.9	-	-	1.02	0.58	3.4	1.9	During hospitalization due to small bowel obstruction treated with laparotomy	Yes

Ca, calcium; Mg, magnesium; IV, intravenous; CT, computed tomography; CNS, central nervous system; RT, radiotherapy; M, male; F, female.